Our vision is to establish a new standard of care for patients suffering with iron deficiency and iron deficiency anemia.
Iron deficiency anemia afflicts a subset of the two billion people worldwide who are nutritionally iron deficientREF. Approximately 10 million people are iron deficient in the United States, including 5 million who have iron deficiency anemia.
Ferric Pyrophosphate Citrate (FPC)
Our innovative therapeutic was developed to replace iron loss in patients with anemia in an entirely different way. Our unique and differentiated molecule, Ferric Pyrophosphate Citrate (FPC), provides a novel mechanism of action with a physiologic approach. FPC donates iron directly to circulating transferrin making it immediately bioavailable for critical body processes, which allows the body to use the iron in a physiologic manner.
This novel approach to the treatment of iron deficiency and anemia has the potential for application in many disease states.
Access our investor center to learn about our strategies to deliver value for the patients we serve, the medical community, our employees and shareholders.Access Now
August 3, 2022
Rockwell Medical to Release Second Quarter 2022 Financial Results on Monday, August 15
WIXOM , Mich. , Aug. 3, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financialRead more
June 22, 2022
Rockwell Medical Provides Corporate and Clinical Update
- Closes $7.5 Million Second Tranche Investment from DaVita - $30 Million in Total Capital Raised This Quarter - Receives Additional Feedback from FDA on its IND Application WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicatedRead more
June 22, 2022
Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer
WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and ChiefRead more
June 7, 2022
Rockwell Medical Closes $15 Million Financing from Leading Healthcare Investor
WIXOM, Mich. , June 7, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (Nasdaq: RMTI) has closed the previously announced $15 Million in financing, consisting of $12 Million in a Registered Direct Offering, and $3 Million in a private investment in public equity (PIPE), both priced at-market, withRead more
June 1, 2022
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
WIXOM , Mich. , June 1, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on May 31, 2022Read more